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IS MARKOV CHAIN/DECISION TREE APPROACH
BETTER THAN COST FUNCTION APPROACH IN
MODELING THE PHARMACEUTICAL COSTS
FOR ATTENTION DEFICIT/HYPERACTIVITY
DISORDER? AN EMPIRICAL STUDY BASED ON A
LARGE CLAIM DATABASE
Sun P, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To examine whether the Markov chain/
decision tree approach is better than the cost function
approach in modeling the pharmaceutical costs for 
Attention Deﬁcit/Hyperactivity Disorder (ADHD).
METHODS: Using one half sample of a nationally rep-
resentative large claim data set (Pharmetrics claim data-
base), we applied both the Markov Chain/decision tree
approach and cost function approach to model the phar-
maceutical costs for attention deﬁcit/hyperactivity disor-
der. Then, we examined both the validity and reliability
of these two models. In terms of validity, we examined
whether and how the model assumptions are satisﬁed
under each approach. In terms of reliability, we used
another half sample of the claim data set to test the two
models. RESULTS: More assumptions were violated in
the Markov chain/decision tree model than in cost func-
tion. One example of these violated assumptions is that
Markov chain/decision tree approach assumes the inde-
pendence of transition probabilities. Furthermore,
because that claim data do not provide many parameters
required in the Markov chain/decision tree model, the
Markov chain/decision tree approach has used many arbi-
trary estimates, which made model very unreliable. The
examples of these parameters are the rate of adequate
response of each medication, the rate of titration up or
down, the rate of switching between medications, the tol-
erable rate of each medication, and drop out rate. CON-
CLUSIONS: The Markov chain/decision tree approach is
not necessary better than cost function approach in mod-
eling pharmaceutical costs. When modelers do not have
solid estimates of those transition probabilities and when
the assumptions underlying this approach are violated,
cost function approach may be better than the Markov
chain/decision tree approach. The limitation of cost func-
tion approach is that it does not give clinical process
information as rich as the Markov chain/decision tree
approach.
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PROBABILISTIC SENSITIVITY ANALYSES:
COMMONLY RECOMMENDED, UNCOMMONLY
PERFORMED
Rocchi A, Chin W
Axia Research, Hamilton, ON, Canada
OBJECTIVE: Guidelines for the economic evaluation of
pharmaceuticals in Canada (CCOHTA, 1997) and the US
(Gold et al., 1996) encourage the use of probabilistic 
sensitivity analyses (SA). Increasingly, the literature also
reports and supports the use of probabilistic SA over the
traditional univariate and multivariate SA. Poster pre-
sentations from the ISPOR May 2002 conference were
reviewed to identify if users were producing the encour-
aged probabilistic SA. It was recognized that abstracts do
not permit comprehensive methodology description, but
given the fundamental importance of SA, it was expected
that minimum information expectations should be met.
METHODS: Abstracts of the ISPOR May 2002 poster
presentations were published in Value in Health
May/June 2002. All abstracts classiﬁed under “Economic
Outcomes” were reviewed to identify original economic
evaluations. Each identiﬁed evaluation was examined for
its reporting and use of SA; these were classiﬁed by SA
methodology (unknown, univariate, multivariate, proba-
bilistic). RESULTS: Of 154 abstracts with economic out-
comes, 50 were original economic evaluations. Of these,
16 (32%) did not mention SA at all. The remaining 34
abstracts (68%) mentioned the use of SA. Of these, 15
(44%) explicitly stated the SA methodology; methodol-
ogy was implicit by results reporting for a further 10
abstracts (29%); methodology was indeterminable for the
ﬁnal 9 abstracts (26%). Of the 25 abstracts for which SA
methodology was determinable, 16 (64%) used only uni-
variate analysis, 8 (28%) used multivariate analysis, and
2 (8%) used probabilistic analysis. CONCLUSIONS:
Despite the encouragement of the literature and guide-
lines, probabilistic SA remain uncommon in economic
evaluations. Moreover, the adequate reporting of SA was
uncommon in the May 2002 ISPOR poster abstracts.
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INCREASING PUBMED YIELD FOR
PHARMACOECONOMIC RESEARCH USING
ITERATIVE SEARCH STRATEGIES
Frame D1, Klawansky S2
1MetaWorks Inc, Medford, MA, USA; 2Harvard School of
Public Health, Boston, MA, USA
OBJECTIVES: With increasing emphasis on using pub-
lished evidence to quantify the value of drug treatment,
we assessed the value of adding search terms identiﬁed
from key articles to initial search strategies to locate
studies in large subject areas. METHODS: Systematic
review in ﬁve chronic disease settings (asthma, depres-
sion, diabetes, GI disorders, and migraine), including
development of pre-deﬁned criteria for study inclusion.
Outcomes of interest were those relevant to the value of
pharmaceutical treatment (economic, societal, and/or
patient beneﬁt). We constructed a MEDLINE search (via
PubMed) with terms indicating drug treatment (“drug
therapy” subheading) and outcomes (“Economics, phar-
maceutical”, “Costs and Cost Analysis,” and “Quality of
life” MeSH terms). We then reviewed indexing terms
present in key articles found independently of the initial
search, using an iterative process. Terms which led to
identiﬁcation of new, relevant citations without excessive
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increase in the total search yield were retained. Supple-
mental electronic (Current Contents, Cochrane, Univer-
sity of York NHS Centre) and manual searches were used
to create a listing of accepted studies for comparison to
the PubMed-only search results. RESULTS: Three thou-
sand six hundred seventy-seven citations were down-
loaded and screened from all sources, resulting in 135
accepted papers across the ﬁve settings (asthma-20,
depression-40, diabetes-16, GI disorders-41, migraine-
18). Using initial search terms, we would have captured
only two-thirds of the eligible studies in our PubMed
search (range 55%–83% by setting). By undergoing the
explorative process to identify additional terms, 90% of
studies (122/135, range 80–100% by setting) were iden-
tiﬁed via PubMed. CONCLUSIONS: Careful iterative
development of search terms should be a component of
all systematic searches in PubMed. Supplemental elec-
tronic and manual searching remains necessary to obtain
a comprehensive study set. PubMed indexing varies by
clinical setting and journal subject, with somewhat
weaker results for pharmacoeconomic/managed care
journals (78%) than disease-speciﬁc (94%) or general
medical (98%) journals.
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ECONOMIC AND OUTCOMES RESEARCH IN
THE REAL WORLD: EVALUATION OF ITS
RELEVANCE
Crawford B1, Baron-Papillon F2, Evans C1,
Horowitz-Mehler N1
1Mapi Values, Boston, MA, USA; 2Mapi Values, Lyon, France
OBJECTIVE: To review the current state of economic
and outcomes research focusing on its application, rele-
vance and communication forums. METHODS: A review
of the literature, web sites and guidelines was performed
to identify examples where economic and outcomes
research was used. A literature search for the top 10
selling drugs in 2000 was also performed to evaluate the
extent of outcomes research in these products’ communi-
cations strategy. RESULTS: As of 2002, 9 countries
required pharmacoeconomic data in reimbursement deci-
sions, 14 countries had informal guidelines and 6 were
under development. Of the top 10 drugs by revenues,
several trends were noted: a decrease in outcomes com-
munication near patent expiration (e.g., omeprazole), a
focus on economic studies rather than PRO when cost
offset was a potential advantage (e.g., celecoxib), an
emphasis on communicating quality of life information
even when drug acquisition costs are high (e.g., epoetin
alpha), and a shift from economic communication, fol-
lowing successful formulary pull-through, to patient sat-
isfaction and quality of life. Internationally, the relevance
of PRO data may be increasing. New strategies for the
use of economic and outcomes data have also been found:
in a class of drugs for intermittent claudication facing a
revision of its reimbursement dossier in France, a positive
PRO study resulted in the change in the package insert
for one product, and that product was the only one its
class to regain market share; examples of the use of eco-
nomic data to avoid de-reimbursement also occurred in
France. Quality issues continue to be a problem in reim-
bursement submissions in several countries (notably 
Australia). CONCLUSION: Economic and outcomes
information is being used in an attempt to improve
market share by answering regulatory requests and in
limited instances may play a crucial role in preserving or
increasing revenues.
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DO PHARMACOECONOMIC FELLOWSHIP
PROGRAMS PROVIDE THE SKILLS NECESSARY
FOR TODAY’S WORK ENVIRONMENT?
Maio V, Loﬂand JH
Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVES: There is limited information on whether
pharmacoeconomic/outcomes research (PE/OR) fellow-
ship programs provide their trainees with an appropriate
set of skills. The objectives are to: 1) identify which
PE/OR skills are most commonly used by former fellow-
ship trainees in their current work setting, and 2) deter-
mine whether former fellowship program participants
ﬁnd their training applicable to their present occupation.
METHODS: A 41-item questionnaire was administered
to former fellows of PE/OR fellowship programs via the
ISPOR website. Former fellows were identiﬁed through
the directories of the American College of Clinical Phar-
macy and ISPOR as well as the website and membership
roll of ISPOR. Individuals were enrolled if they 1) com-
pleted a PE/OR program at least 3 months prior to initi-
ation of the survey, and 2) were currently employed.
RESULTS: Of the 61 respondents meeting the inclusion
criteria, 56% completed a PE/OR fellowship program
after 1999; 55% and 20% work in the pharmaceutical
industry and academia, respectively. Respondents spent
27% and 32% of their time performing PE and OR,
respectively. Respondents were actively involved in the
conceptualization (74%), operationalization (54%), and
data management (67%) of research projects. Overall,
90% of the respondents were satisﬁed with their PE/OR
fellowship experience, and 92% stated that the program
provided the necessary skills for their work setting. PE,
decision analysis and modeling, and OR were cited as the
most essential topics needed for their current occupation.
CONCLUSIONS: According to former fellows, it appears
that the current skill sets provided in PE/OR fellowship
programs prepare individuals for today’s work environ-
ment within the ﬁeld of PE/OR. These ﬁndings help
demonstrate that PE/OR fellowships are valuable train-
ing programs.
